. Author manuscript; available in PMC: 2016 Sep 13.

Published in final edited form as: Am J Med Sci. 2016 Feb 23;351(5):513–519. doi: 10.1016/j.amjms.2016.02.030

Table 1.

Maximal dilatory responses (Emax) and half maximal effective concentration (EC50) to produce vascular dilation of phenylephrine-preconstricted renal interlobular arteries for 14,15-EET and the two analogs.

14,15-EETs	Shams, n=7	2K1C, n=6
Emax (%)	62.8 ± 4.4	41.7 ± 6.6^*
EC50 (nM)	16.8 ± 10	16.9 ± 9
14,15-EET analog	Shams n=9	2K1C n=9
Emax	49.8 ± 7.2	30.1 ± 2.8^*
EC50 (nM)	18 ± 10	55 ± 17
11,12-ether-EET-8ZE	Shams n=6	2K1C n=7
Emax	80.8 ± 6.5	31.4 ± 6.4 ^*
EC50 (μM)	0.26 ± 0.22	0.25 ± 0.24

14,15-EET analog: sodium (S)-2-(Z)-(13-(3-pentyl)ureido)-tridec-8(Z)-enamido)succinate, an agonistic orally-active analog of 14,15-epoxyeicosatrienoic acid, 11,12-ether-EET-8ZE: 11-nonyloxy-undec-8(Z)-enoic acid, an analog of 11,12-epoxyeicosatrienoic acid, Emax – maximal response, EC50 – concentration of drug which produces 50% response

P<0.05 versus sham-operated rats.